Supplementary Table 1-2, Supplementary Figure 1 from Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer

Wei, Xiao X.; Chan, Stephen; Kwek, Serena; Lewis, Jera; Dao, Vinh; Zhang, Li; Cooperberg, Matthew R.; Ryan, Charles J.; Lin, Amy M.; Friedlander, Terence W.; Rini, Brian; Kane, Christopher; Simko, Jeffry P.; Carroll, Peter R.; Small, Eric J.; Fong, Lawrence

doi:10.1158/2326-6066.22538605.v1

- No file added yet -

Supplementary Table 1-2, Supplementary Figure 1 from Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer

journal contribution

posted on 2023-04-03, 23:10 authored by Xiao X. Wei, Stephen Chan, Serena Kwek, Jera Lewis, Vinh Dao, Li Zhang, Matthew R. Cooperberg, Charles J. Ryan, Amy M. Lin, Terence W. Friedlander, Brian Rini, Christopher Kane, Jeffry P. Simko, Peter R. Carroll, Eric J. Small, Lawrence Fong

Supplementary Table 1: Antibodies used in flow cytometry Supplementary Table 2: Antibodies used in immunohistochemistry Supplementary Figure 1: Pre-treatment biopsy and post-treatment RP Gleason scores

Funding

NIH

Peter Michael Foundation

History

ARTICLE ABSTRACT

Granulocytic–macrophage colony-stimulating factor (GM-CSF) is used as an adjuvant in cancer vaccine trials and has the potential to enhance antitumor efficacy with immunotherapy; however, its immunologic effects are not fully understood. Here, we report results from a phase I study of neoadjuvant GM-CSF in patients with localized prostate cancer undergoing radical prostatectomy. Patients received subcutaneous injections of GM-CSF (250 μg/m2/day) daily for 2 weeks (cohort 1; n = 6), 3 weeks (cohort 2; n = 6), or 4 weeks (cohort 3; n = 6). Treatment was well tolerated with all grade 1 or 2 adverse events. Two patients had a decline in prostate-specific antigen (PSA) of more than 50%. GM-CSF treatment increased the numbers of circulating mature myeloid dendritic cells, proliferating conventional CD4 T cells, proliferating CD8 T cells, and to a lesser magnitude FoxP3+ regulatory CD4 T cells. Although GM-CSF treatment did not augment antigen-presenting cell localization to the prostate, treatment was associated with recruitment of CD8+ T cells to the tumor. These results suggest that systemic GM-CSF can modulate T-cell infiltration in the tumor microenvironment. Cancer Immunol Res; 4(11); 948–58. ©2016 AACR.

Usage metrics

Keywords

Clinical Trial Results Genitourinary Cancers Prostate cancer Immunology Cytokines Immunomodulation

Licence

CC BY

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Supplementary Table 1-2, Supplementary Figure 1 from Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer

Funding

NIH

Peter Michael Foundation

History

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports